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Abstract
Acute spinal cord injury initiates a complex cascade of molecular events termed ‘secondary injury’, which leads to
 progressive degeneration ranging from early neuronal apoptosis at the lesion site to delayed degeneration of intact
 white matter tracts, and, ultimately, expansion of the initial injury. These secondary injury processes include, but are
 not limited to, inflammation, free radical-induced cell death, glutamate excitotoxicity, phospholipase A2 activation, and
 induction of extrinsic and intrinsic apoptotic pathways, which are important targets in developing neuroprotective
 strategies for treatment of spinal cord injury. Recently, a number of studies have shown promising results on
 neuroprotection and recovery of function in rodent models of spinal cord injury using treatments that target secondary
 injury processes including inflammation, phospholipase A2 activation, and manipulation of the PTEN-Akt/mTOR
 signaling pathway. The present review outlines our ongoing research on the molecular mechanisms of neuroprotection
 in experimental spinal cord injury and briefly summarizes our earlier findings on the therapeutic potential of
 pharmacological treatments in spinal cord injury.
Keywords: spinal cord injury, neuroprotection, inflammation, oxidation, apoptosis, glucocorticoid receptor,
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Research Highlights
The review outlines our ongoing research on the molecular mechanisms of neuroprotection in spinal cord injury and
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 briefly summarizes our earlier findings on the therapeutic potential of pharmacological treatments in spinal cord injury.
Abbreviations
TNF-α, tumor necrosis factor-α; AP-1, activator protein-1; NF-κB, nuclear factor kappa B; ANXA1, annexin A1; iNOS,
 inducible nitric oxide synthase; MMP-1, matrix metalloproteinase-1; MP, methylprednisolone; GR, glucocorticoid
 receptor; mTOR, mammalian target of rapamycin
INTRODUCTION
Traumatic spinal cord injury leads to neurological deficits and motor and sensory dysfunctions. In the United States
 alone, there are approximately 265 000 people living with spinal cord injury in 2010, and an additional 12 000 new
 spinal cord injury cases occur every year (https://www.nscisc.uab.edu). Clinically, most traumatic spinal cord injuries
 are anatomically incomplete and the primary impact-induced secondary damage contributes significantly to the final
 extent of neural damage and ultimately to the extent of the long term disability, which represent an important target in
 developing neuroprotective strategies for treatment of spinal cord injury[1,2,3]. Neuroprotection aims at preventing or
 attenuating secondary injury.
Understanding the intimate mechanisms of secondary injury after traumatic spinal cord injury should provide us with a
 large number of therapeutic targets. For the last two decades, our research has focused on elucidating the molecular
 mechanisms that mediate secondary spinal cord injury and exploring novel neuroprotective strategies. The present
 review outlines our ongoing research on the molecular mechanisms of neuroprotection in experimental spinal cord
 injury and briefly summarizes our earlier findings on the therapeutic potential of a few promising pharmacological
 treatments for spinal cord injury.
INFLAMMATION
Post-traumatic inflammatory reaction has been shown to contribute to progressive tissue damage after spinal cord
 injury. Following spinal cord injury, inflammatory cells such as polymorphonuclear neutrophils, macrophages, and
 lymphocytes quickly infiltrate into the traumatized cord, and inflammatory mediators, such as eicosanoids and
 cytokines, are accumulated[4,5,6,7,8,9,10,11]. For example, within a few minutes post-spinal cord injury, eicosanoids
 such as TXA2 and PGE2 increased in the injured cord tissue[7,9]. Within the first hour post-spinal cord injury,
 neutrophil infiltration[4,5,12] and cytokine expression such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-
1β) at and surround the site of injury occurred[8,10,11]. The interplay between inflammatory cells and mediators likely
 perpetuates a progressive course of secondary injury, resulting in neuronal and glial cell death, axonal destruction and
 functional loss.
Activator protein-1 (AP-1) and nuclear factor kappa B (NF-κB) are two major pro-inflammatory transcription factors
 that are activated in inflammation[13,14]. NF-κB and AP-1 act individually or in synergy to transactivate genes that
 code for pro-inflammatory proteins such as cytokines and adhesion molecules, pro-inflammatory enzymes including
 inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase II, and pro-inflammatory proteases[13,14].
 We[11,15] and others[16] have shown that both AP-1 and NF-κB were activated after spinal cord injury in a rat model.
 Electrophoretic mobility shift assay showed that AP-1 binding activity increased after spinal cord injury, starting at 1
 hour, peaking at 8 hours, and declining to basal levels by 7 days[15]. After spinal cord injury, NF-κB binding activity
 was also increased, peaked between 1 and 3 days post-injury[11]. Post-traumatic inflammatory reaction is a protracted
 process lasting for days to weeks. The time course of AP-1 and NF-kB activation in the present study is compatible for
 AP-1 and NF-kB to play an important role in triggering the subsequent inflammatory activities. AP-1 is a dimer
 composed of various Fos and Jun family proteins[17,18]. Immunostaining showed an increase in the expression of the
 Fos-B and c-Jun components of AP-1 in the injured cord[15]. These constituent components of AP-1 were not only
 localized to the cytosol but also in nuclei[15], suggesting their nuclear translocation to form the AP-1 transcription
 factor. The specificity of spinal cord injury -induced AP-1 activation was further confirmed by an antisense strategy
 directed at c-fos that blocked AP-1 activation after spinal cord injury[15]. AP-1 and NF-κB, functioning as pro-
inflammatory transcription factors, transactivate a number of genes that are expressed in inflammation[14,19] including
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 matrix metalloproteinase-1 (MMP-1)[20,21] and MMP-9[22,23]. Western blotting and immunostaining showed
 increased expression of MMP-1 and MMP-9 in the injured cord. Both MMP-1 and MMP-9 were expressed with high
 intensity in neurons and glial cells after spinal cord injury. These findings were consistent with changes of both AP-1
 and NF-κB following spinal cord injury. It has been shown that excessive MMP expression leads to increased capillary
 permeability in numerous neurological disorders such as multiple sclerosis, infection, and ischemia[24]. Alteration of
 vascular permeability, a key feature of inflammation, has been shown after spinal cord injury[25]. The activation of two
 key pro-inflammatory transcription factors, NF-κB and AP-1, after spinal cord injury provides an underlying molecular
 mechanism for a post-traumatic inflammatory reaction.
TNF-α is a key inflammatory mediator, which plays a pathogenetic role in cell death in neurodegenerative diseases[26].
 In both mouse and rat traumatic spinal cord injury models, an increase in TNF-α expression in the injured cord has been
 demonstrated at both the mRNA and protein levels as early as hours after injury[11,27,28,29]. Western blot analysis
 revealed that TNF-α expression began at 4 hours post-injury, peaked at 24 hours (4.5-fold increase at 1 day after spinal
 cord injury, P < 0.01) and declined at 3 days after spinal cord injury, which were confirmed by
 immunohistochemistry[11]. Immunofluorescence double labeling further revealed that within hours after spinal cord
 injury, increased TNF-α immunoreactivity was localized in neurons, astrocytes, oligodendrocytes, microglia, and
 endothelial cells in areas of the spinal cord adjacent to the lesion site, which was confirmed by
 immunoelectronmicroscopy[30]. Myelin breakdown was noted in oligodendrocytes that are immunopositive for
 TNF-α[30]. TNF-α exerts its effector actions, at least partially, through the activation of a pro-inflammatory
 transcription factor, NF-κB (Figure 1), which in turn upregulates such genes as iNOS, cytokines, adhesive molecules,
 and others[13]. Post-traumatic TNF-α expression was accompanied by an increase in NF-kB binding activity in nuclear
 proteins isolated from the injured cord (3.9-fold increase, P < 0.01)[11].
The effect of TNF-α is mediated through its receptors TNFR1 (p55) and TNFR2 (p75). In a rat traumatic spinal cord
 injury model, we demonstrated that the expression of TNFR1 and TNFR2 was slightly increased at 15 minutes post-
injury, reached the peak at 4 hours for TNFR2 (6.06-fold, P < 0.01) and 8 hours for TNFR1 (3.58-fold, P < 0.01), and
 declined markedly after 1 and 3 days[31]. Spatially, TNFR1- and TNFR2-IR were initially observed at the impact site,
 spread to the distant areas during the peak expression, and confined to the lesion area at later time points[31]. TNFR1
 and TNFR2 were localized in neurons, oligodendrocytes, and astrocytes[31]. These results suggest that the expression
 of TNFR1 and TNFR2 after spinal cord injury may contribute to post-traumatic inflammatory responses of TNF-α. Our
 result further showed that methylprednisolone (MP), a clinically used glucocorticoid, mediated neuroprotection after
 spinal cord injury by inhibiting expression of TNF-α and TNFRs[11,31], suggesting TNF-α and TNFRs have
 deleterious effects.
However, our experiments also suggest a neuroproctive role of TNF-α in spinal cord injury[32]. Deletion of TNFR1 in
 knockout mice inhibited NF-κB binding activity, reduced cellular inhibitor of apoptosis protein 2 (c-IAP2) expression
 and increased the active form of caspase-3. After spinal cord injury, the TNFR1(-/-) mice had greater numbers of
 apoptotic cells, a larger lesion size, and worse functional recovery than wild-type mice. TNFR2-deficient mice had a
 similar, although not as pronounced, consequence as the TNFR1(-/-) mice. These findings support the argument that the
 TNFR-NF-κB pathway is beneficial for limiting apoptotic cell death after spinal cord injury and that a defective TNFR-
NF-κB pathway results in a poorer neurological outcome. A worse functional outcome in TNFR(-/-) mice suggests that
 an endogenous apoptosis inhibitory mechanism mediated by TNFR activation, NF-κB, and c-IAP2 may be of
 pathophysiological importance. Conversely, our previous results and others suggested that neuroprotection of MP after
 spinal cord injury was achieved by inhibiting activation of NF-κB and its associated downstream induction of nitric
 oxide (NO) synthase[11,33]. These findings suggest that TNF-α may have deleterious effects, particularly early after
 injury, but are also critical for neural repair as the injury evolves, which is consistent with the concept of dual effects of
 the inflammatory response[34,35,36,37,38]. Thus, an effective therapeutic intervention must limit the acute destructive
 effects of the inflammatory response while also preserving its neuroprotective effects.
NEUROPROTECTION AND MECHANISMS OF MP ACTION
MP, a synthetic glucocorticoid, is the only drug used clinically to improve neurological function in patients with acute
 spinal cord injury. MP is also a potent anti-inflammatory agent. The mechanism of MP action is not fully understood,
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 but our studies showed several possible mechanisms of MP. First, MP inhibits spinal cord injury -induced TNF-α
 expression and NF-κB activation via a glucocorticoid receptor (GR) mechanism (Figure 1)[11,15,39]. In the contusive
 rat spinal cord injury model, TNF-α expression and NF-κB activation have been shown to increase after spinal cord
 injury[11]. NF-κB activation is initiated by pro-inflammatory signaling processes such as TNF-α interaction with
 TNF-α receptor on the cell surface. The TNF-α-initiated signals trigger the phosphorylation of IκBα, which leads to its
 dissociation from NF-κB, allowing the latter to translocate into the nucleus[40]. Most significantly, MP (30 mg/kg, i.v.)
 given immediately after spinal cord injury reduced TNF-α expression by 55% (P < 0.01) and NF-κB binding
 activity[11]. MP at a dose of 30 mg/kg has also been shown to be effective in improving functional outcomes in rat
 spinal cord injury models[33,41]. MP also partially inhibited the injury-induced expression of TNFR1 and TNFR2, an
 effect which could be reversed by RU486, an antagonist of GR[31]. RU486 has also been shown to reverse MP
 inhibition of NF-κB activation[15]. Immunofluorescence double staining revealed a colocalization of GR and TNF-α in
 neurons and glial cells[39]. These findings are consistent with an anti-inflammatory role of MP in spinal cord injury.
 MP inhibition of NF-κB function is likely mediated by the induction of IκB, which traps NF-κB in inactive cytoplasmic
 complexes[42]. Second, MP inhibits post-traumatic AP-1 activation via a GR mechanism (Figure 1)[15]. Thus, for MP
 to inhibit NF-κB and AP-1 activation, it has to bind to GR. RU486, a GR antagonist, reversed MP inhibition of AP-1
 activation after spinal cord injury[15]. Furthermore, RU486 also reversed MP inhibition of MMP-1 and MMP-9
 expression after spinal cord injury[15]. These findings are again consistent with the contention that AP-1 and NF-κB
 are required to transactivate MMP-1 and MMP-9 and therefore are subjected to the inhibitory action of MP via a GR
 mechanism. Third, MP induces anti-inflammatory genes such as annexin A1 (ANXA1), interleukin 10, MAPK
 phosphatase I, secretory leukocyte protease inhibitor, and I-κB (Figure 1)[43,44].
POSSIBLE MECHANISMS OF GR IN MEDIATING TRAUMATIC
 SPINAL CORD INJURY
The GR is an intracellular receptor, which is present in the cytoplasm and nucleus of neurons and glial cells. GR can
 function both as a transcription factor that binds to glucocorticoid response elements (GREs) in the promoters of
 glucocorticoid responsive genes to activate their transcription, and as a regulator of other transcription factors (Figure
 1)[43,44,45]. This receptor is typically found in the cytoplasm, but upon ligand binding, is transported into the nucleus.
 The glucocorticoids including MP bind to the cytosolic GR to form activated GR (aGR)[43]. The aGR has two
 principal mechanisms of action, transactivation of anti-inflammatory genes and transrepression of pro-inflammatory
 genes (Figure 1)[43,44,45]. The aGR translocates into the nucleus and binds to specific GREs in the promoter regions
 of anti-inflammatory genes such as ANXA1, interleukin 10, MAPK phosphatase I, secretory leukocyte protease
 inhibitor, and I-κB. This mechanism of action is referred to as transactivation of anti-inflammatory genes. The
 dominant anti-inflammatory effect of aGR is derived from aGR transrepression of pro-inflammatory genes, namely
 protein-protein interaction or crosstalk with other transcription factors, notably NF-κB and AP-1.
Glucocorticoids bind to intracellular GR, which in turn bind to GRE to exert ligand-activated transcription effects. Thus,
 glucocorticoid actions depend not only on the ligand concentration but also on the extent of GR expression. In the
 central nervous system (CNS) of normal adult rats, a widespread distribution of GR-IR has been demonstrated[46,47].
 After spinal cord injury, an increased expression of GR was found in both the cytoplasm and nucleus of affected cells
 after spinal cord injury[39]. Immunohistochemistry and western blot analysis revealed an increase in GR protein
 expression as early as 15 minutes after injury. GR expression sharply increased at 4 hours (22-fold), peaked at 8 hours
 (56-fold), rapidly declined at 1 day, and returned to the baseline level at and after 3 days[39]. During its peak
 expression, GR was localized in neural somata and dendrites but not in axons and their terminals[39]. GR
 immunoreactivity was also found in oligodendrocytes and astrocytes. Interestingly, other cell types, such as endothelial
 cells, were GR-negative. Furthermore, the nuclear protein binding activity to GRE based on EMSA was significantly
 increased after injury[39]. These results suggest that, after spinal cord injury, GR expression is followed by
 translocation and transcription activity involving GRE. Finally, colocalization of GR and TNF-α was observed in
 neurons and glial cells, consistent with MP regulation of TNF-α in this model[11,39]. ANXA1 is a glucocorticoid-
inducible protein, which inhibits the activity of phospholipase A2 (PLA2), and hence reduces the generation of pro-
inflammatory eicosanoids. Our subsequent studies showed that expression of ANXA1 increased following spinal cord
 injury[48] and administration of ANXA1 reduced spinal cord injury -induced inflammatory response and tissue damage
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 through inhibition of PLA2[49]. These findings may provide new insights into the anti-inflammatory action of MP.
REACTIVE OXYGEN SPECIES AND OXIDATIVE STRESS
Oxidative injury is a common mechanism of damage in CNS neurological disorders including spinal cord injury.
 Reactive oxygen species (ROS) such as hydrogen peroxide (H2 O2, an inducer of ROS)[50], superoxide (O2•-)[51], and
 hydroxyl radical (•OH)[52] all increased significantly in the spinal cord following injury and could occur within hours
 after spinal cord injury[53]. Excessive ROS production causes oxidative damage to proteins, lipids and DNA, followed
 by impaired cellular functions that eventually lead to severe and irreversible cell death[54]. NO is a short-lived free
 radical gas. The NO reacts with superoxide to generate an extremely potent ROS, peroxynitrite, that can damage
 cellular enzymes, membranes, and subcellular organelles through the nitration of tyrosine residues on proteins[55].
 iNOS is a key enzyme that catalyzes the synthesis of NO. Nitrotyrosine (NT) is an indirect chemical indicator of toxic
 NO and peroxynitrite-induced cellular damage[55]. In our study[56], we observed a progressive increase in iNOS
 expression in the injured cord in a rat spinal cord injury model, starting at 1 day with maximal expression occurring at 7
 days, as determined by western blot analysis. iNOS expression corresponded temporally to an increase in iNOS enzyme
 activity after spinal cord injury. In parallel with the progressive increase in iNOS activity, NT expression also increased
 over time after spinal cord injury. The iNOS and NT immunoreactivity was localized in neurons, astrocytes, endothelial
 cells and ependymal cells at the epicenter and adjacent to the region of spinal cord impact and injury. The increased
 expression of iNOS after spinal cord injury is consistent with spinal cord injury-induced NF-κB activation[11] which
 transactivates specifically the gene coding for iNOS, suggesting that NF-κB may activate iNOS gene transcription,
 which leads to iNOS protein expression after spinal cord injury. The inhibition of NO production with NOS antiserum
 reduces cell death after acute spinal cord injury[57]. The role of NOS in secondary injury is further supported by
 evidence of functional improvement and tissue sparing in NOS deficient mice[58]. These results suggest that the free
 radical formation is also an important therapeutic target for spinal cord injury.
APOPTOSIS
As early as 1997, we and others demonstrated that apoptosis is as an important mechanism of cell death after spinal cord
 injury[59,60]. Apoptosis of both neurons and glia contributes to spinal cord tissue damage after traumatic insults of
 mild to moderate severity[59]. Our determination of apoptosis relies on multiple criteria: morphology under both light
 and electron microscopic examination, nuclear chromatin staining with Hoechst 33342 dye and with TUNEL, DNA
 laddering. Within minutes after mild weight drop impact (a 10-gm weight falling 6.25 mm), neurons in the immediate
 impact area showed a loss of cytoplasmic Nissl substances. Over the next 7 days, this lesion area expanded and
 cavitated. TUNEL-positive neurons were noted primarily restricted to the gross lesion area 4-24 hours after injury, with
 a maximum presence at 8 hours after injury. TUNEL-positive glias were present at all stages studied between 4 hours
 and 14 days, with a maximum presence within the lesion area 24 hours after injury. However, at 7 days post-injury, a
 second wave of TUNEL-positive glial cells was noted in the white matter peripheral to the lesion and extending at least
 several millimeters away from the lesion center. The suggestion of apoptosis was supported by electron microscopy, as
 well as by nuclear staining with Hoechst 33342 dye, and by examination of DNA prepared from the lesion site.
 Furthermore, repeated intraperitoneal injections of cycloheximide, beginning immediately after a 12.5-mm weight drop
 insult, produced a substantial reduction in histological evidence of cord damage and in motor dysfunction assessed 4
 weeks later. These findings support the hypothesis that apoptosis dependent on active protein synthesis contributes to
 the neuronal and glial cell death, as well as to the neurological dysfunction, induced by mild-to-moderate severity
 traumatic insults to the rat spinal cord. Thus, blocking apoptosis is a neuroprotective approach for treatment of spinal
 cord injury.
PLA2 AS A NOVEL TARGET FOR INTERVENTION AFTER SPINAL
 CORD INJURY
PLA2 is a diverse family of lipolytic enzymes that hydrolyze an ester bond at the sn-2 position of phospholipids that
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 generates a free fatty acid such as arachidonic acid and a lysophospholipid such as lysophosphatidylcholine (Lyso-PC)
[61,62,63]. Arachidonic acid can give rise to eicosanoids via cyclooxygenase (COX-1 and -2) and 5-lipoxygenase (5-
LO) enzymes. Eicosanoids such as prostaglandins, thromboxanes, and leukotrienes are potent mediators of
 inflammation and tissue damage implicated in pathological states of numerous acute and chronic neurological
 disorders[61,62]. In addition, Lyso-PC is a myelinolytic agent and can act as a chemoattractant for immune
 cells[61,62,63]. To date, more than 19 isoforms of PLA2 have been found in the mammalian system which can be
 classified into three major categories: secretory PLA2 (sPLA2), cytosolic PLA2 (cPLA2) and Ca2+-independent PLA2
 (iPLA2)[61,62]. All of the major PLA2s were found to be expressed in the mammalian brain and spinal cord. Our series
 of studies have shown that PLA2 contribute to secondary pathogenesis after spinal cord injury (Figure 2)[61,62].
First and foremost, we found that PLA2 activity and expression were induced by spinal cord injury, peaking at 4 hours
 after injury and remaining significantly increased at 7 days[64]. Additionally, cPLA2 protein, an important isotype
 involved in lipid mediator generation, was also increased and peaked at 3 and 7 days after injury[64]. This isotype was
 localized in neurons, swollen axons, oligodendrocytes, and a subpopulation of microglia. Another important isotype,
 sPLA2-IIA involved in inflammation and demyelination, was increased at both mRNA and protein levels, peaking at 1
 and 4 hours after the injury[65]. This isotype was localized in neurons, axons, oligodendrocytes, astrocytes, and some
 myelin rings.
To remove the confounding effects of injury, we directly injected PLA2 into the intact spinal cord[64,66,67]. This
 resulted in dose-dependent and sustained impairment in motor function[64]. Subsequent anatomical analyses revealed
 that injection of PLA2 induced demyelination[64,66,67] and such effect could be effectively attenuated with mepacrine,
 a PLA2 inhibitor[64]. Our experiments further showed that exogenous administration of PLA2 induced inflammatory
 and oxidative responses, as evidenced by increased expression of the inflammatory mediators TNF-α and IL-1β as well
 as 4-hydroxy-2(E)-nonenal, a product of lipid peroxidation and marker for oxygen free-radical-mediated membrane
 injury[64]. In vitro experiments revealed that exogenous PLA2 induced cultured spinal neuronal death in a dose-
dependent manner, which was substantially reversed by mepacrine, the PLA2 inhibitor[64].
To further confirm the role of PLA2 in secondary pathogenesis after spinal cord injury, we investigated neuroprotective
 effects of ANXA1, a PLA2 inhibitor in a rat spinal cord injury model[49].
The results showed that injections of ANXA1 into the acutely injured spinal cord at 2 concentrations (5 and 20 µg)
 inhibited spinal cord injury -induced increases in PLA2 and myeloperoxidase activities. In addition, ANXA1
 administration reduced the expression of interleukin-1β and activated caspase-3 at 24 hours, and glial fibrillary acidic
 protein at 4 weeks postinjury. Furthermore, ANXA1 administration significantly reversed PLA2-induced spinal cord
 neuronal death in vitro and reduced tissue damage and increased white matter sparing in vivo. ANXA1 administration
 also protected axons of long descending pathways as evidenced by increased numbers of Fluorogold-labeled neurons in
 selected superspinal nuclei. ANXA1 administration also significantly increased the number of animals that responded
 to transcranial magnetic motor-evoked potentials. These results, particularly the improvements obtained in tissue
 sparing and electrophysiologic measures, suggest PLA2 is a novel target for treatment of spinal cord injury, which is
 supported by inhibition of cPLA2 activation-mediated the protective effect of Ginkgo biloba extract (EGb761)[68].
PLA2 is induced by several toxic factors that are generated in the injured cord including inflammatory cytokines, free
 radicals, and EAAs[61,62]. Our in vitro experiments showed that both H2O2 and glutamate induced cPLA2 activation
 and neuronal death, and such effects were significantly reversed by arachidonyl trifluromethyl ketone (ATK), a cPLA2
 inhibitor[68]. It is conceivable that PLA2 acts as a common pathway for multiple key mechanisms of secondary spinal
 cord injury, making it an attractive therapeutic target to improve tissue repair and functional recovery.
PTEN-AKT/MTOR SINGLING PATHWAY IN NEUROPROTECTION
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PTEN-Akt/mTOR singling pathway is involved in cell survival (Figure 3).
Phosphatase and tensin homolog (PTEN) is dual phosphatase that converts phosphatidylinositol (3,4,5)-trisphosphate
 (PIP3) into phosphatidylinositol (4, 5)-bisphosphate (PIP2), thus inhibiting downstream Akt and mammalian target of
 rapamycin (mTOR) signaling. Activation of phosphoinositide 3-kinases can phosphorylate and convert the PIP2 into
 PIP3, which in turn activates Akt and mTOR. PTEN inactivation has been shown to activate different downstream
 pathways such as Akt and mTOR, signalling and inhibit other signalling molecules such as GSK-3[69]. Recent studies
 demonstrated that deletion of either PTEN or tuberous sclerosis complex 1, both of which constitutively activate mTOR
 exerts strong neuroprotective and axon-growth-promoting effects on injured retinal ganglion cells[69,70].
 Bisperoxovanadium compounds, PTEN inhibitors, have proven neuroprotective effects in several central nervous
 system injury/disease models[71,72,73]. More recent experiments in our laboratory showed that blocking PTEN with
 bisperoxovanadium produced neuroprotection and functional recovery following cervical unilateral contusive spinal
 cord injury[74]. In this study, two experimental groups of rats were established to (1) assess twice-daily 7 day treatment
 of the bisperoxovanadium, potassium bisperoxo (picolinato) vanadium, on long-term recovery of skilled forelimb
 activity using a novel food manipulation test, and neuroprotection 6 weeks following injury and (2) elucidate an acute
 mechanistic link for the action of the drug post-injury. The results showed that bisperoxovanadium promoted
 significant neuroprotection through reduced motorneuron death, increased tissue sparing, and minimized cavity
 formation in rats. Enhanced forelimb functional ability during a treat-eating assessment was also observed.
 Additionally, bisperoxovanadium significantly enhanced downstream Akt and mTOR signaling and reduced autophagic
 activity, suggesting inhibition of the phosphatase and tensin homologue deleted on chromosome 10 as a potential
 mechanism of bisperoxovanadium action following traumatic spinal cord injury. Overall, this study demonstrates the
 efficacy of a clinically applicable pharmacological therapy for rapid initiation of neuroprotection after spinal cord
 injury, and sheds light on the signaling involved in its action.
EFFECT OF GLIAL CELL LINE-DERIVED NEUROTROPHIC
 FACTOR (GDNF) ON NEUROPROTECTION
GDNF, a distant member of the transforming growth factor-β superfamily, has potent neuroprotective and neurotrophic
 effects on several neuronal cell types in both the central and peripheral nervous systems, which are mediated by a
 multisubunit receptor system consisting of a glycosyl-phosphatidylinositol-linked high-affinity ligand-binding
 coreceptor, GFRα1, and the transmembrane protooncogene, c-Ret[75,76,77,78]. Our experiments also show that GDNF
 has a neuroprotective effect on spinal cord tissues and axons of long descending pathways in adult rats after spinal cord
 injury[79]. Our results demonstrated that constant intrathecal infusion of the two concentrations of GDNF resulted in
 (1) GDNF's penetration and diffusion into the cord parenchyma surrounding the injury, (2) a 34–42% reduction of the
 total lesion volume measured using a stereological method, (3) a 10–13% increase in the percent of spared white matter
 measured at the injury epicenter, and (4) a substantial increase in the number of neurons from selective proprio- and
 supraspinal regions whose axons traverse the lesion and innervate the lumbar cord. These results are consistent with a
 recent study demonstrating that focal injections of GDNF into the spinal cord 1–2 mm rostral and caudal to a T9-10
 contusive spinal cord injury significantly improved Basso Beattie Bresnahan locomotor rating scores and reduced
 neuronal cell death[80].
NEUROPROTECTION OF TESTOSTERONE ON MOTONEURON
 AND MUSCLE MORPHOLOGY
It has been shown that testosterone has neuroprotective and neurotherapeutic effects after a variety of motoneuron
 injuries[81,82,83,84]. Treatment with testosterone also improves motor function in spinal cord injury patients. Patients
 treated with testosterone had higher American Spinal Injury Association (ASIA) discharge motor scores, a result
 ascribed to either improved strength through the anabolic effects of testosterone on skeletal muscle or its
 neuroprotective/neuroregenerative effects[85]. Recently, we found that testosterone had similar beneficial effects in
 adult rats after spinal cord injury[86]. In this study, adult female rats received either sham or T9 spinal cord contusion
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 injuries and were implanted with blank or testosterone-filled Silastic capsules. Four weeks later, motoneurons
 innervating the vastus lateralis muscle of the quadriceps were labeled with cholera toxin-conjugated horseradish
 peroxidase, and dendritic arbors were reconstructed in three dimensions. Contusion injury resulted in large lesions, with
 no significant differences in lesion volume, percent total volume of lesion, or spared white or gray matter between
 spinal cord injury groups. Spinal cord injury with or without testosterone treatment also had no effect on the number or
 soma volume of quadriceps motoneurons. However, spinal cord injury resulted in a decrease in dendritic length of
 quadriceps motoneurons in untreated animals, and this decrease was completely prevented by treatment with
 testosterone. Similarly, the vastus lateralis muscle weights and fiber cross-sectional areas of untreated spinal cord injury
 animals were smaller than those of sham-surgery controls, and these reductions were both prevented by testosterone
 treatment. No effects on motor endplate area or density were observed across treatment groups. These findings suggest
 that regressive changes in motoneuron and muscle morphology seen after spinal cord injury can be prevented by
 testosterone treatment, further supporting a role for testosterone as a neurotherapeutic agent in the injured nervous
 system.
MICRORNAs (miRNAs) AS NOVEL TARGETS FOR TREATMENT OF
 SPINAL CORD INJURY
miRNAs are a novel class of small non-coding RNAs that negatively regulate gene expression at the posttranscriptional
 level by binding to the 3’ untranslated region (UTR) of target mRNAs leading to their translational inhibition or
 degradation of the target[87]. Recent evidence suggests that expression of at least 20–30% of human protein-coding
 genes is modulated by miRNAs[88]. A large number of miRNAs are present in the mammalian brain and spinal cord,
 where they play key roles in neurodevelopment and are likely to be important mediators of plasticity[88,89,90,91].
 Some miRNAs have been implicated in several neurological diseases[87,90]. Several studies also suggest the
 possibility of miRNA involvement in neurodegeneration[87].
In 2009, we first reported the dysregulated expression of a larger set of miRNAs in the spinal cord following traumatic
 injury[92], supported by subquentic studies on miRNA expression after spinal cord injury[93,94]. These altered
 miRNAs can be classified into 3 categories: (1) up-regulation, (2) down-regulation and (3) an early up-regulation at 4
 hours followed by down-regulation at 1 and 7 days post-spinal cord injury[92]. The bioinformatics analysis indicates
 that the potential targets for miRNAs altered after spinal cord injury include genes encoding components that are
 involved in the inflammation, oxidation, and apoptosis that are known to play important roles in the pathogenesis of
 spinal cord injury[92]. These findings suggest that abnormal expression of miRNAs may contribute to the pathogenesis
 of spinal cord injury and is a potential target for therapeutic interventions following spinal cord injury.
Although the roles of miRNAs in spinal cord injury remain to be determined, increasing evidence suggests that miRNAs
 represent a new class of drug targets[95,96,97]. Inhibition of a particular miRNA linked to spinal cord injury with
 miRNA inhibitor can remove the block against expression of a therapeutic protein and conversely, administration of a
 miRNA mimetics can boost the endogenous miRNA population repressing a detrimental gene. For example, PTEN is a
 direct target of miR-21[98]. miR-21 mimics may exert neuroprotective effects on spinal cord injury by inhibition of
 PTEN (Figure 3). Taking advantage of their small size and the current knowledge of miRNA biogenesis, modified
 RNAs can be transiently delivered as a synthetic, preprocessed miRNA or anti-miRNA oligonucleotide[87]. Several
 studies have shown the potential of customized miRNA inhibitors to target specific pathologic miRNAs, both in vitro,
 and more importantly in vivo[96,99]. The anti-miRNA oligonucleotides are single stranded reverse complement
 oligonucleotides. The stability, binding affinity and specificity of these oligonucleotides have been improved through
 chemical modification[87]. The miRNA mimics are small, usually double stranded and chemically modified
 oligonucleotides which can be used to down-regulate a specific target protein[87]. Although there are many challenges
 for miRNAs as therapeutic targets such as delivery, potential off-target effects and safety, the strategy of miRNA
 manipulation in vivo to regulate disease-related processes is already becoming a feasible future therapeutic approach.
 Thus, miRNA is an attractive target for therapeutic interventions following spinal cord injury.
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Figures and Tables
Figure 1
Schematic drawing illustrates possible actions of glucocorticoids (GC) and glucocorticoid receptors (GR) after acute
 spinal cord injury.
GC bind to GR to form activated GR (aGR) in the cytosol, which displaces heat-shock protein 90 (HSP90) and allows
 receptor dimerization, movement into the nucleus, and binding to the glucocorticoid response elements (GRE). This
 leads to transactivation of anti-inflammatory genes such as IκB and ANXA1.
IκB then sequesters NF-κB, preventing it from activating transcription of pro-inflammatory cytokines. ANXA1 inhibits
 cytosolic phospholipase A2 (cPLA2) activity, in turn reduces pro-inflammatory mediators such postaglandins. In
 addition, the aGR can interact with AP-1 and NF-κB directly to suppress pro-inflammatory mediators and cytokine
 production.
AP-1: Activator protein-1; NF-κB: nuclear factor kappa B; MMP-1: matrix metalloproteinase-1; MMP-9: matrix
 metalloproteinase-9; Inos; Inducible nitric oxide synthase; NO: nitric oxide; ANXA1: annexin A1; TNFR: tumor
 necrosis factor receptor; IκB: inhibitor of NF-κB.
Figure 2
Schematic drawing shows possible role of cPLA2 in SCI.
SCI induces cPLA2 expression and activation by several toxic factors that are generated in the injured cord including
 inflammatory cytokines, free radicals, and excitatory amino acids.
Over-activation of cPLA2 induces cell death and tissue injury though several mechanisms.
First, cPLA2 induces membrane damage through hydrolysis of neural membrane phospholipids, resulting in alternation
 of membrane function such as fluidity and permeability, behavior of transporters and receptors, and calcium overload,
 and, eventually, leading to functional failure of excitable membranes.
Second, cPLA2 hydrolyzes membrane phospholipids to produce arachdonic acid (AA), then AA can give rise to pro-
inflammatory mediators, for example eicosanoids, such as prostaglandins, thromboxanes, and leukotrienes.
Third, cPLA2-induced AA and NADPH oxidase lead to ROS production. ANXA1, ATK and EGb761 reduce neuronal
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 death and tissue damage though inhibition of cPLA2.
cPLA2: Cytosolic phospholipase A2; AA: arachdonic acid; SCI: spinal cord injury; AA: arachdonic acid ANXA1:
 annexin A1; ATK: arachidonyl trifluromethyl ketone; EGb761: Ginkgo biloba extract; ROS: Reactive oxygen species;
 NADPH: nicotinamide adenine dinucleotide phosphate.
Figure 3
Schematic drawing shows PTEN-Akt/mTOR singling pathway in SCI.
PTEN's phosphatase converts phosphatidylinositol (3,4,5)-trisphosphate (PIP3) into phosphatidylinositol (4,5)-
bisphosphate (PIP2), thus inhibiting downstream Akt and mTOR signaling.
PI3K converts PIP2 into PIP3, which can then activate Akt and mTOR, thus enhancing p-S6 expression leading to
 neuroprotection. Bisperoxovanadium (bpV) and miR-21 may induce Akt/mTOR activation by inhibition of PTEN,
 finally exert neuroprotective effects.
PTEN: phosphatase and tensin homolog; mTOR: mammalian target of rapamycin; SCI: spinal cord injury; PI3K:
 phosphoinositide 3-kinases; S6: ribosomal protein S6.
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